ASPIC

Uncertainty exists regarding Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) of patients with metastatic colorectal cancer (mCRC) treated with cetuximab or bevacizumab. We conducted a prospective cohort study comparing PROs and HRQoL from both therapies. This study included 44 patients treated for the first time with one of the strategies, whose PROs scoring for internationally validated questionnaires were compared at three sequential timepoints: baseline, 6-week, and 12-week assessments.

Authors and affiliations:

Susana Proença^1,2,†Bernardo Antunes^1,† Rita C. Guedes¹ Filipa Ramilo-Gomes^1,3 M. Fátima Cabral¹ Judite Costa¹ Ana S. Fernandes⁴ Matilde Castro¹ Nuno G. Oliveira¹ and Joana P. Miranda^1,†*

¹ Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal

O papel das metaloproteinases de matriz (MMPs) na migração e invasão de células de cancro tem sido correlacionado com a agressividade tumoral, destacando-se entre outras, as MMP-2/9. Neste trabalho, dois macrociclos contendo grupos piridina ([15]pyN₅ e [16]pyN₅) foram sintetizados, caracterizados quimicamente e testados como potenciais inibidores destas enzimas no âmbito da terapêutica do cancro de mama, utilizando modelos celulares 2D e 3D desenvolvidos no nosso laboratório.

In the last years, the research team of Ângela Sousa has been focused on the development of biotechnological strategies with therapeutic potential for cervical cancer treatment. The development of this disease is strongly associated with infection by Human Papillomavirus (HPV), being the latter responsible for the production of E6 and E7 oncoproteins. These proteins have the ability of interfering with cellular regulatory mechanisms fueled by tumor suppressor proteins, such as p53 and pRB proteins.

Nos últimos anos, a equipa de investigação de Ângela Sousa tem-se focado no desenvolvimento de estratégias biotecnológicas com potencial terapêutico no tratamento de cancro do colo do útero. O desenvolvimento desta doença está fortemente associado à infeção pelo Vírus do Papiloma Humano (HPV), sendo que este último é responsável pela produção das oncoproteínas E6 e E7.

The lack of a sensitive and specific biomarker for early detection of prostate cancer (PCa) is a major obstacle to the effective treatment of these patients. This study aimed to study the volatile urinary metabolic profile of PCa patients (n=58) and control individuals (cancer-free, n=60), to identify a potential panel of biomarkers for non-invasive PCa detection. The results obtained revealed a panel of biomarkers with 6 volatile compounds, which was able to identify this type of cancer with a sensitivity, specificity and accuracy of 89%, 83% and 86%, respectively.

A falta de um biomarcardor sensível e específico para a deteção precoce do cancro da próstata constitui um obstáculo ao tratamento eficaz destes doentes. Este trabalho pretendeu estudar o perfil metabólico volátil de urinas de doentes com cancro da próstata (n=58) e de indivíduos controlo (sem cancro, n=60), com o objetivo de identificar um potencial painel de biomarcadores para a deteção não invasiva do cancro da próstata.

Authors and Affiliations:

João Lobo ^1,2,3, Ângelo Rodrigues ^1,2,3, Rita Guimarães ^1,2, Mariana Cantante ^1,2, Paula Lopes ^1,2, Joaquina Maurício ⁴, Jorge Oliveira ⁵, Carmen Jerónimo ^2,3,*,# and Rui Henrique ^1,2,3,*,#

¹ Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal